Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 20/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 18/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 11/20 | 0.67 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL471473 | 0.92 | OPRD1 (0.69) | OPRD1KCNH2CYP2D6MRGPRX2OPRK1 | |
| SCHEMBL10258789 | 0.86 | OPRD1 (0.78) | OPRD1KCNH2CYP2D6MRGPRX2OPRK1 | |
| SCHEMBL471640 | 0.85 | OPRD1 (0.89) | OPRD1KCNH2CYP2D6MRGPRX2OPRK1 | |
| SCHEMBL10258990 | 0.83 | OPRD1 (0.71) | OPRD1KCNH2CYP2D6MRGPRX2OPRK1 | |
| SCHEMBL10257763 | 0.82 | OPRD1 (0.55) | OPRD1KCNH2CYP2D6MRGPRX2OPRK1 | |
| SCHEMBL12030722 | 0.81 | OPRD1 (0.73) | OPRD1KCNH2CYP2D6MRGPRX2OPRK1 | |
| SCHEMBL12262194 | 0.80 | OPRD1 (0.51) | OPRD1KCNH2CYP2D6MRGPRX2OPRK1 | |
| SCHEMBL467369 | 0.80 | OPRD1 (1.00) | OPRD1KCNH2CYP2D6OPRK1OPRM1 | |
| SCHEMBL10258597 | 0.80 | OPRD1 (0.71) | OPRD1KCNH2CYP2D6MRGPRX2OPRK1 | |
| SCHEMBL467495 | 0.80 | OPRD1 (0.82) | OPRD1KCNH2CYP2D6MRGPRX2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2399577-A1 | Use of N-containing spirocompounds for the enhancement of cognitive function | Adolor Corporation (US) | 2011-12-28 | — | — | EP | disclosed |
| WO-2008033299-A2 | USE OF N-CONTAINING SPIROCOMPOUNDS FOR THE ENHANCEMENT OF COGNITIVE FUNCTION | ADOLOR CORPORATION (US) | 2008-03-20 | — | — | WO | disclosed |